Qtrex Quantum Ltd. · NASDAQ:QTEX
Qtrex Quantum — Inspira Technologies OXY B.H.N. — Investor Presentation (January 2022)
55 slides from Qtrex Quantum's investor presentation, Jan 6, 2022
Slide 1: About ART System
About ART™ i . ystem (IRL CIIROT am
Slide 2: Forward Looking Statement
This presentation contains express or implied forward - looking statements pursuant to U.S. Federal securities laws. For example, the Company is using forward - looking statements when it discusses the ART’s potential benefits, the ART business model, its vision, the design of ART, advantages of the
Slide 3: The ART System and About Inspira
Th e A R T Ρ S y st e m* ● A novel early - stage extracorporeal approach ● Potentially minimize the need for invasive mechanical ventilation (MV) ● Designed to be applied in awake & spontaneously breathing patients භ භ ● The oxygenation and carbon dioxide removal respiratory system substituting MV ,
Slide 4: Vision: Redefining Artificial Respiration
Vision Redefining Artificial Respiration to impact millions of lives Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved
Slide 5: A New Approach to Minimize the Need for Mechanical Ventilation
A New Approach to Minimize the Need for Mechanical Ventilation Inspira’s ART Ρ System * Awake Patient Cannula Insertion Hemo - dynamic extracorporeal treatment Discharge Mechanical Ventilation IV sedation Intubation Artificial Respiration Ventilator Associated Complications Weaning Discharge * These
Slide 6: Extracorporeal approach
Extracorporeal approach A first - in - class system specifically designed to provide continuous low - flow venous - venous extracorporeal respiratory support Cannula is designed to draw blood at a rate of 1 - 1.5L per minute¹ Rapid oxygenation improvement & CO2 removal O2 saturation level is raised
Slide 7: The Cannula
Small diameter Dual lumen cannula, 16 - 21Fr in diameter* One entry point, reduces risks of bleeding and infections Simple placement Cannula is inserted to the jugular vein and positioned in the superior vena cava, above the right atrium Reduces the need for medical personnel who are specialized in
Slide 8: Plug and play disposable cartridge and auto-priming
A novel “plug and play” disposable cartridge • Minimize the need for a perfusionist to put together disposable parts • Any nurse can insert cartridge and operate the system A Novel auto - priming system • Priming is done automatically • Designed to prevent human errors • Minimize the need for a perf
Slide 9: ART's Proprietary Hemo-Protective Flow Technology
A R T ’ s P r opri e t a r y H e m o - P r o t ec t i v e Flow Technology Features Bloo d p r o t e ct io n 1 - 1.5 liters of blood are being enriched with oxygen, rebalance patient’s oxygen saturation levels in minutes¹ A R T ’ s d es i g n e d f e a t u r e s Hemolysis reduction Thrombosis reducti
Slide 10: Pre-Clinical Results
“I was able to witness the insertion and positioning of the ART cannula, which was completed without the need for imaging. The ART system’s capability to elevate oxygen saturation levels in a stable fashion, and all within a minute, is outstanding ”. Prof. Eli Gabbay, Professor of Respiratory Medici
Slide 11: What Proprietary Components Are We Developing?
What Proprietary Components Are We Developing?
Slide 12: ART System Primary Components
Dual Lumen Cannula Hemo - Protective Flow Pump Component : Proprietary hemo - protective pump; designed to prevent hemolysis and thrombosis Initiation System Disposable Respiratory Support Unit Component : Plug - and - play disposable cartridge. suitable for deployment both in ICUs and general medic
Slide 13: Proprietary Disposable Cartridge
Plug & play cartridge Auto priming system (included in cartridge) • Fully assembled, ready to use disposable set cartridge - all parts are included. Designed to allow for a faster response time by reducing assembly complexity. • The simplicity of the design has the potential to reduce human error wh
Slide 14: Proprietary Low Flow Centrifugal Pump Head
Pump head - sterile magnetic coupling pump - head for one time use, specifically designed for low flow Low priming volume higher velocity reduces friction duration Anti - coagulation coating Clotting prevention Reduction of sheer forces Hemolysis reduction Designed for increased blood velocity under
Slide 15: Proprietary Control Unit
• Controls and orchestrates multiple hemodynamic measurements documented via sensors ,TCH SO 2 , CO 2 , PaO 2 hemoglobin, blood temp and blood flow. • Designed to allow both auto control and manual control ekilnu( commercial ECMO system which are only controlled manually) Proprietary Control Unit Th
Slide 16: Proprietary Dual Lumen Cannula
Proprietary Dual Lumen Cannula Designed for low volume and high velocity ,prevents clotting 16 - 21 French diameter • Cannula is designed to be insert by an ICU practitioner. Minimize the need for a surgeon Short in length ,inserted into the jugular vein Anticoagulant coating Dual lumen cannula desi
Slide 17: What Differentiates ART From ECMO?
What Differentiates ART Ρ From ECMO?
Slide 18: ART vs. ECMO
ART Ρ Vs. ECMO • Patient population • Cannulation • Mechanical design of device and cannula • Patient sedative state • Ventilator induced lung injury • Hospital’s prior experience with ECMO • Market size
Slide 19: What is ECMO?
What is ECMO (Extracorporeal Membrane Oxygenation)? Extracorporeal Membrane Oxygenation (ECMO) is a life support machine. People who need ECMO have a severe and life - threatening illness that stops their heart or lungs from working properly. For example, ECMO is used during life - threatening condi
Slide 20: ECMO: Patients' Level of Severity
E C M O* ECMO is a salvage therapy VV - ECMO¹ is used when all other forms of lung support have failed for critically ill patients ART has the potential to prevent invasive mechanical ventilation and its associated long - term damages ART might be applied in (1) patient prior invasive mechanical ven
Slide 21: ART vs. ECMO: Cannulation
ART Ρ System Vs. ECMO: Cannulation Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved ECMO* ART Ρ System Two single lumen cannulas Typically, two large (21 - 25 fr) single lumen cannulas are used to withdraw and return 5 - 7 liters of blood per minute . (Commercially a
Slide 22: ART vs ECMO: Safety Optimization of Low Blood Flow
ART Ρ System Vs ECMO: Safety Optimization of Low Blood Flow E C M O* Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved ART Ρ System A high flow device is not designed to support low flow treatment ECMO treatment cessation, is characterized by short duration of low blo
Slide 23: ART vs. ECMO: Sedation & Paralysis
ART Ρ System Vs. ECMO: Sedation & Paralysis ECM O * Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved Patients are sedated and paralyzed Patients are mechanically ventilated, sedated and paralyzed when ECMO is first administered Patients are awake and spontaneously br
Slide 24: ART vs. ECMO: Ventilator Induced Lung Injury
ART Ρ System Vs. ECMO: Ventilator Induced Lung Injury E C M O * Ventilator induced lung injury is highly prevalent Patients are mechanically ventilated prior to ECMO administration, as well as during ECMO treatment period Patients may be awake and spontaneously breathing ART may potentially prevent
Slide 25: ART vs. ECMO: Hospital's Prior Experience With ECMO
ART Ρ System Vs. ECMO: Hospital’s Prior Experience With ECMO ECM O * ECMO treatment is limited to hospitals with relevant know how and accumulated experience: ICU physicians, perfusionist and trained ICU nurses must operate and monitor a patient treated with ECMO. ECMO cannot be operated in the abse
Slide 26: ART vs. ECMO: The Market
ART T Ρ System Vs. ECMO: The Market ECMO* The number of patients treated with ECMO is limited: 1. ECMO is a salvage treatment 2. High rate of bleeding and infection complications 3. Expensive ART’s potential patient population includes all patients considered candidates for MV. ART will potentially
Slide 27: The Unmet Need: Who Can Benefit From ART Treatment
The Unmet Need Who Can Benefit From ART TM Treatment
Slide 28: Acute Respiratory Failure: Current Treatment Paradigm
Acute Respiratory Failure: Current Treatment Paradigm Acute Respiratory Failure Hypoxemia Hypercarbia Hypoxemia & Hypercarbia RESPIRATORY DETERIORATIO • Nasal m ask • F a c e m ask • Nasal p lu g s • BI P AP C P AP Non - Invasive Ventilation¹ ECMO³ (selected pt.) Extracorporeal Membrane Oxygenation
Slide 29: Mission: Alternative for Invasive Mechanical Ventilation
Our mission is to provide an alternative for invasive mechanical ventilation for acute respiratory patients who continue to deteriorate following non - invasive ventilation treatment. ▪ Non - invasive ventilation (NIV) - is the delivery of oxygen (ventilation support) via a face mask and therefore e
Slide 30: Mechanical Ventilation Risks and Complications
1. Am J Respir Crit Care Med Vol. 196, P3 - 4, 2017. ATS Patient Education Series © 2017 American Thoracic Society 2. Diling Wu et al. Frontiers in pharmacology MINI REVIEW published: 09 May 2019. doi: 10.3389/fphar.2019.00482 3. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hos
Slide 31: Why Prevent Invasive Ventilation: Ventilator-Induced Lung Injury
Why Is It Important to Prevent Invasive Ventilation? 1 - UpToDate July 2021 Lung injury can be an adverse consequence of mechanical ventilation. This injury is called ventilator - induced lung injury (VILI) and can result in pulmonary edema, barotrauma, and worsening hypoxemia that can prolong mecha
Slide 32: Ventilator-Induced Diaphragmatic Dysfunction
Why Is It Important to Prevent Invasive Ventilation? 1 - UpToDate July 2021 Mechanical ventilation itself causes diaphragmatic muscle atrophy; a phenomenon called ventilator induced diaphragmatic dysfunction (VIDD) 1 . Controlled mechanical ventilation may lead to a very rapid type of disuse atrophy
Slide 33: Ventilator-Associated Pneumonia
Ventilator - associated pneumonia (VAP) 1 is a type of hospital - acquired pn develops after more than 48 hours of mechanical ventilation. VAP is a com in the intensive care unit that is associated with an increased risk of death eumonia (HAP) that mon and serious problem Why Is It Important to Prev
Slide 34: Negative Consequences of Sedation
Administration of analgesia and sedation to ensure patient comfort and facilitate mechanical ventilation must be balanced against the known negative consequences of excessive sedation Deep sedation, especially early during mechanical ventilation, is associated with prolonged time to liberation from
Slide 35: Why Is It Important to Shorten Invasive Ventilation?
Why Is It Important to Shorten Invasive Ventilation? 1 Marini, John J., and Patricia RM Rocco. "Which component of mechanical power is most important in causing VILI?." (2020): 1 - 3. 2 Hermans, Greet, et al. "Increased duration of mechanical ventilation is associated with decreased diaphragmatic fo
Slide 36: Who Can Benefit From The ART System?
Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved Who Can Benefit From The ART Ρ System? Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved
Slide 37: ART Offers Two Intervention Modalities
ART Ρ Device Offers Two Intervention Modalities Patients deteriorating with noninvasive ventilation treatment, would be treated with ART 1. 2. Prevent mechanical ventilation Avoid: VALI, VIDD and VAP 1. 2. Shorten mechanical ventilation period Reduce VALI, VIDD and VAP W h en Where I CU Medical ward
Slide 38: Possible Indications
Possible Indications ART TM may be used for the treatment of acute respiratory failure patients leading to hypoxemia, hypercarbia or both who continue to deteriorate following non - invasive ventilation ARDS Pneumonia Ast h ma COPD Copyr C ig o h p t y © rig 2 h 0 t 1 © 8 - 201 2 8 1 - I 2 n 0 s 2 p
Slide 39: Potential Advantages: The Patient's Perspective
ART TM may be applied during non - invasive ventilation stage to prevent mechanical ventilation: patient is awake, mobile and breathes spontaneously ● Immediate oxygen saturation elevation and stabilization ● Decreased breathing efforts ● Patient can eat and drink ● Patient can communicate their sym
Slide 40: Potential Advantages: Patient's Perspective, Ventilated Patients
ART TM treatment* may be added to mechanically ventilated patients ● Reduction of ventilation period ● Less aggressive ventilation – less PEEP, less driving pressures >>> reduced barotrauma and volutrauma ● Reduction of forms of complications associated with MV ● Reduction of mortality rate Potentia
Slide 41: Potential Advantages: The Hospital Perspective
● Minimize the need for a medical team with prior experience with extracorporeal respiratory systems ● Reduced length of stay >>Increased patient throughput ● Reduced staffing ● Smaller Cannula (compared to ECMO’s cannulas) may prevent the need for surgical access team ● Reduced costs associated wit
Slide 42: Potential Advantages: The Medical Team Perspective
● Clinicians would be able to offer an alternative to mechanical ventilation ● Self priming system results in less human errors ● No prior extracorporeal respiratory systems experience is needed ● Cannula size will allow ICU physicians to insert it without a surgeon involvement Potential Advantages
Slide 43: Initial Pre-Clinical Studies (In-vivo)
Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved Initial Pre - Clinical Studies (In - vivo) Dr. Revital Tuval, PhD
Slide 44: Pre-Clinical Study Background
In August 2020, initial pre - clinical animal studies were performed on swine model at LAHAV CRO in Israel. 25 hypoxemic events were induced, in order to test ARTs’ oxygenation and carbon dioxide removal capabilities. In 20 out of the 25 hypoxemic events induced, ART treatment was provided with a bl
Slide 45: Method
M e thod In these initial pre - clinical studies (In - vivo) the goal was to assess the oxygenation effectiveness of ART system¹ in animal model. Pump Oxygenator The swine species chosen for the current studies was Large - White X Landrace. This breed was chosen due to a well - known resemblance of
Slide 46: Data Collected
Data Collected Clinical and physiological parameters were collected throughout the test . Oxygenation was assessed by means of a non - invasive sensor (PPG - Sat), and blood gas measurements . Both arterial and venous blood were drawn and analyzed using the GEM 4000 Blood Gas Analyzer (Werfen, Barce
Slide 47: Study Design
ART turned ON 15 minutes Blood flow: 1 liter/min ART turned OFF Hypoxemia induction (~3 - 5 min) Study design 1 Hyp o x e mia induction (ART is OFF) 2 3 Blood samples are taken from the (1) femoral vein (2) pulmonary artery (3) carotid artery at baseline (prior to the activation of ART) and 15 minut
Slide 48: Study Results
Study Results I n sp i r a T e c hn ol ogi e s OX Y B .H.N. LT D. , Al l ri g h ts re se rv e d 2018 - 2022 Copyr i g h t ©
Slide 49: ART Provides Significant Increase In Saturation
ART Provides Significant Increase In Saturation 0.48 Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved 0.72 0.93 1.00 0.90 0.80 0.70 0.60 0.50 0.40 0.30 0.20 0.10 0.00 Femoral vein Pulmonary artery Car ot i d ar t e ry SvO2 & SaO2_ART in ON mode ART oxygenation Lung o
Slide 50: ART's Contribution to Oxygen Saturation
ART’s Contribution to Oxygen Saturation Should Be Reviewed Independently From the Lung Activity • ART increases arterial oxygen saturation from 85% to 93%. However, increase in arterial saturation is attributed to both ART and lung activity. • The contribution of ART to saturation should be assessed
Slide 51: ART Provides Significant Increase In PO2 Levels
ART Provides Significant Increase In PO2 Levels 24.8 Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved 28.5 27.4 38.2 49.7 63.6 20.0 10.0 0.0 30.0 40.0 50.0 60.0 70.0 OFF Femoral vein ON Femoral vein OFF Pu l m o n ary artery ON Pu l m o n ary artery OFF Carotid arter
Slide 52: CO2 Removal Via ART Is Significant
CO2 Removal Via ART Is Significant 45.00 40.00 35.00 30.00 25.00 20.00 15.00 10.00 5.00 0.00 Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved 40.53 36.74 38.33 29.83 33.5 27.75 OFF Femoral vein ON Femoral vein OFF Pu l m o n ary artery ON Pu l m o n ary artery OFF Ca
Slide 53: Blood Pressure Was Unaffected
Blood Pressure Was Unaffected 72.4 80.8 72.4 72.4 80.8 68.0 70.0 72.0 74.0 76.0 78.0 80.0 82.0 OFF Femoral vein ON Femoral vein OFF Pu l m o n ary artery ON Pu l m o n ary artery OFF Car ot i d ar t e ry ON Car ot i d ar t e ry SBP(mmHg) 80.8 46.9 Copyright © 2018 - 2022 Inspira Technologies OXY B.H
Slide 54: Conclusion
54 Copyright © 20 C 1 o 8 p - y 2 r 0 ig 2 h 2 t © In 2 s 0 p 18 ir - 2 a 02 T 1 e I c n h sp n ir o a l T o e g ch ie no s lo O gi X es Y O B XY .H B . .H N .N . . L L T T D D. . , , A A ll l r l ig r h ig ts h r t e s se r r e ve s d erv 5 e 4 d Conclusion ART treatment in hypoxemic animal model,
Slide 55: Thank You
Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved Thank You
Inspira Technologies OXY B.H.N. — Investor Presentation (January 2022) on 6ix